<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951662</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA 1UH2AA026218</org_study_id>
    <nct_id>NCT03951662</nct_id>
  </id_info>
  <brief_title>Immunology of HIV and Alcoholic Hepatitis</brief_title>
  <official_title>Effects of Alcoholic Hepatitis on Immunological and Virological Profiles in HIV-Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, longitudinal cohort study involving HIV-positive, antiretroviral&#xD;
      (ART)-treated, heavy alcohol drinking participants who have and do not have alcoholic&#xD;
      hepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the relationships between alcohol&#xD;
      consumption and HIV-related pathogenic processes (microbial translocation, immune activation,&#xD;
      inflammation, HIV replication, and hepatitis). Two study groups will be assembled and&#xD;
      followed longitudinally over one year to address this objective. Group 1 will include&#xD;
      HIV-positive, ART-treated, heavy alcohol drinkers who have alcoholic hepatitis. Group 2 will&#xD;
      include HIV-positive, ART-treated, heavy alcohol drinkers who do not have alcoholic&#xD;
      hepatitis. Both groups will undergo similar study procedures and follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding ended&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune activation - Levels of sCD14, sCD163</measure>
    <time_frame>One year</time_frame>
    <description>Levels of sCD14, sCD163</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>With alcoholic hepatitis</arm_group_label>
    <description>HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without alcoholic hepatitis</arm_group_label>
    <description>HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alcoholic Hepatitis Group</intervention_name>
    <description>Alcoholic hepatitis is defined as having a total bilirubin level &gt;3mg/dL and AST level&gt;50U/L</description>
    <arm_group_label>With alcoholic hepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heavy Drinking Controls without Hepatitis</intervention_name>
    <description>Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly</description>
    <arm_group_label>Without alcoholic hepatitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC, plasma, serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 patients with HIV infection who are receiving antiretroviral therapy and who are heavy&#xD;
        drinkers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both Groups: Age equal to or greater than 18 years&#xD;
&#xD;
          -  HIV infection documented by any licensed rapid HIV test or HIV enzyme or&#xD;
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and&#xD;
             confirmed by a licensed Western blot, a second antibody test by a method other than&#xD;
             the initial rapid HIV and/or E/CIA, or by at least one detectable HIV-1 RNA level&#xD;
&#xD;
          -  Receipt of stable antiretroviral therapy of any kind for at least 90 days prior to the&#xD;
             baseline study visit&#xD;
&#xD;
          -  The most recent HIV-1 RNA level must be &lt;200 copies/mL obtained as part of routine&#xD;
             clinical care within 90 days prior to the main study visit&#xD;
&#xD;
          -  NOTE: There is no CD4 cell count eligibility criterion for this study.&#xD;
&#xD;
          -  Current alcoholism defined as &gt;40g/day and &gt;60g/day of alcoholic intake on average for&#xD;
             a minimum of six months and within 90 days of the baseline visit in women and men,&#xD;
             respectively&#xD;
&#xD;
          -  For Group 1 (Alcoholic Hepatitis Group), the presence of alcoholic hepatitis is&#xD;
             defined by&#xD;
&#xD;
               -  Per most recently obtained routine clinical care laboratories, a total bilirubin&#xD;
                  &gt; 3mg/dL and AST &gt;50U/L, both within 90 days of the baseline study visit&#xD;
&#xD;
               -  For Group 1, participants who have become alcohol abstinent within 14 days of the&#xD;
                  baseline visit will still be allowed to participate&#xD;
&#xD;
          -  For Group 2 (Heavy drinking controls without hepatitis):&#xD;
&#xD;
               -  The most recent AST, ALT, and total bilirubin levels must be within normal&#xD;
                  limits. However, if the bilirubin level is increased due to suspected Gilbert's&#xD;
                  syndrome or due to current use of atazanavir, then the participant will be&#xD;
                  eligible.&#xD;
&#xD;
               -  There must not be evidence of current hepatosplenomegaly by examination or&#xD;
                  imaging obtained previously&#xD;
&#xD;
               -  There must not be stigmata of cirrhosis (spider angiomata, jaundice,&#xD;
                  encephalopathy, palmar erythema, ascites, intestinal varices).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to complete written, informed consent&#xD;
&#xD;
          -  Incarceration at the time of screening or main study visit&#xD;
&#xD;
          -  Abstinence from alcohol &gt;2 weeks prior to the baseline study visit&#xD;
&#xD;
          -  Liver disease considered to be due to any etiology besides alcohol use&#xD;
&#xD;
          -  Diagnosed disease or process associated with increased systemic inflammation&#xD;
             (including, but not limited to, systemic lupus erythematosus, inflammatory bowel&#xD;
             diseases, other collagen vascular/autoimmune diseases)&#xD;
&#xD;
          -  Known active hepatitis B (defined as hepatitis B surface antigen positive with&#xD;
             quantifiable HBV DNA viral load) or active hepatitis C (defined as quantifiable&#xD;
             hepatitis C RNA viral load)&#xD;
&#xD;
          -  Fever, defined as T â‰¥ 38.0C within 48 hours prior to any study visit&#xD;
&#xD;
          -  Therapy for acute infection or other serious medical illnesses within 7 days of study&#xD;
             visit&#xD;
&#xD;
          -  Malignancy requiring active treatment or had completed treatment within 90 days of any&#xD;
             study visit (excluding skin-limited Kaposi sarcoma)&#xD;
&#xD;
          -  Pregnancy or breastfeeding within 14 days of any study visit&#xD;
&#xD;
          -  Receipt of investigational agents, cytotoxic chemotherapy, systemic or topical&#xD;
             glucocorticoids (of any dose), or anabolic steroids (including physiologic&#xD;
             testosterone replacement therapy) within 14 days of study visit&#xD;
&#xD;
          -  Active illicit drug use (besides marijuana) via any intake route (inhalation, smoking,&#xD;
             injection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Infectious Diseases Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

